Baseline characteristics of responders to lenalidomide: type and duration of responses
| No. . | WHO . | Cytogenetics . | IPSS . | BM blasts, % . | Baseline platelet count, G/L . | Hematologic response (IWG 2006) . | Cytogenetic response . | Achievement of transfusion independence . | Duration of response, mo . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RAEB2 | del 5q | High | 15 | 105 | CR | Complete | Yes | 18.5+ |
| 2 | RAEB2 | del 5q | Int-2 | 17 | 136 | CR | Complete | Yes | 12 |
| 3 | AML | del 5q, +8 | High | 29 | 123 | CR | Complete | Yes | 2 |
| 4 | RAEB2 | del 5q | Int-2 | 15 | 216 | CR | Partial | Yes | 11.5 |
| 5 | RAEB2 | del 5q | Int-2 | 18 | 178 | CR | Partial | Yes | 11.5+ |
| 6 | RAEB2 | del 5q | Int-2 | 16 | 163 | CR | Complete | Yes | 9.5 |
| 7 | RAEB2 | del 5q | Int-2 | 13 | 499 | CR | Partial | Yes | 6.5 |
| 8 | RAEB1 | del 5q and 4 additional abnormalities | Int-2 | 8 | 81 | Marrow CR | No | No | 3.5 |
| 9 | RAEB1 | del 5q, +8,+21 | Int-2 | 7 | 312 | Marrow CR | Complete | Yes | 14.5+ |
| 10 | AML (RAEB-T) | del 5q, del 7q, del 9p | High | 28 | 67 | SD with HI-E | No | Yes | 5 |
| 11 | RAEB2 | del 5q, t(3;5) | High | 19 | 70 | SD with HI-E | Not done | Yes | 2 |
| 12 | RAEB1 | del 5q, del 13q | Int-2 | 7 | 112 | SD with HI-E | Partial | Yes | 3.5 |
| 13 | RAEB1 | del 5q, del 11q | Int-2 | 9 | 90 | SD with HI-E | Not done | Yes | 6.5 |
| No. . | WHO . | Cytogenetics . | IPSS . | BM blasts, % . | Baseline platelet count, G/L . | Hematologic response (IWG 2006) . | Cytogenetic response . | Achievement of transfusion independence . | Duration of response, mo . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RAEB2 | del 5q | High | 15 | 105 | CR | Complete | Yes | 18.5+ |
| 2 | RAEB2 | del 5q | Int-2 | 17 | 136 | CR | Complete | Yes | 12 |
| 3 | AML | del 5q, +8 | High | 29 | 123 | CR | Complete | Yes | 2 |
| 4 | RAEB2 | del 5q | Int-2 | 15 | 216 | CR | Partial | Yes | 11.5 |
| 5 | RAEB2 | del 5q | Int-2 | 18 | 178 | CR | Partial | Yes | 11.5+ |
| 6 | RAEB2 | del 5q | Int-2 | 16 | 163 | CR | Complete | Yes | 9.5 |
| 7 | RAEB2 | del 5q | Int-2 | 13 | 499 | CR | Partial | Yes | 6.5 |
| 8 | RAEB1 | del 5q and 4 additional abnormalities | Int-2 | 8 | 81 | Marrow CR | No | No | 3.5 |
| 9 | RAEB1 | del 5q, +8,+21 | Int-2 | 7 | 312 | Marrow CR | Complete | Yes | 14.5+ |
| 10 | AML (RAEB-T) | del 5q, del 7q, del 9p | High | 28 | 67 | SD with HI-E | No | Yes | 5 |
| 11 | RAEB2 | del 5q, t(3;5) | High | 19 | 70 | SD with HI-E | Not done | Yes | 2 |
| 12 | RAEB1 | del 5q, del 13q | Int-2 | 7 | 112 | SD with HI-E | Partial | Yes | 3.5 |
| 13 | RAEB1 | del 5q, del 11q | Int-2 | 9 | 90 | SD with HI-E | Not done | Yes | 6.5 |
All patients were dependent on RBC transfusions at the onset of treatment.
BM indicates bone marrow; RAEB, refractory anemia with excess blasts; AML, acute myeloid leukemia; High, high risk; Int-2, intermediate 2 risk; del, deletion; t, translocation complex; CR, hematologic complete remission; SD, stable disease; and HI-E, hematologic improvement erythroid.